Serum Amyloid P and a Dendritic Cell–Specific Intercellular Adhesion Molecule-3–Grabbing Nonintegrin Ligand Inhibit High-Fat Diet–Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice
Open accessAbstract
High-fat diet (HFD)-induced inflammation is associated with a variety of health risks. The systemic pentraxin serum amyloid P (SAP) inhibits inflammation. SAP activates the high-affinity IgG receptor Fcγ receptor I (FcγRI; CD64) and the lectin receptor dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN; CD209). Herein, we show that for mice on an HFD, injections of SAP and a synthetic CD209 ligand (1866) reduced HFD-increased adipose and liver tissue inflammation, adipocyte differentiation, and lipid accumulation in adipose tissue. HFD worsened glucose tolerance test results and caused increased adipocyte size; for mice on an HFD, SAP improved glucose tolerance test results and reduced adipocyte size. Mice on an HFD had elevated serum levels of IL-1β, IL-23, interferon (IFN)-β, IFN-γ, monocyte chemoattractant protein 1 [MCP-1; chemokine (C-C motif) ligand 2 (CCL2)], and tumor necrosis factor-α. SAP reduced serum levels of IL-23, IFN-β, MCP-1, and tumor necrosis factor-α, whereas 1866 reduced IFN-γ. In vitro, SAP, but not 1866, treated cells isolated from white fat tissue (stromal vesicular fraction) produced the anti-inflammatory cytokine IL-10. HFD causes steatosis, and both SAP and 1866 reduced it. Conversely, compared with control mice, SAP knockout mice fed on a normal diet had increased white adipocyte cell sizes, increased numbers of inflammatory cells in adipose and liver tissue, and steatosis; and these effects were exacerbated on an HFD. SAP and 1866 may inhibit some, but not all, of the effects of a high-fat diet.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SAP/PTX2 is primarily produced in the liver in physiological conditions in humans.
“Previous studies have shown that SAP/PTX2 is primarily produced in the liver in physiological conditions in humans81–83.”
From Serum amyloid P secreted by bone marrow adipocytes drives skeletal amyloidosis (2025) · cites this paper as [81]
The introductory passage identifies SAP as PTX2 and discusses its plasma levels in patients, while the section on brown fat and liver examines liver inflammation and steatosis in mice. Neither states where SAP is primarily produced in healthy humans. Searches for liver production, hepatocyte synthesis, and physiological conditions found no passage addressing that point; page numbers were unavailable in our copy. (LLM, conf=0.72)
Experimental — accuracy not yet measuredSerum amyloid P has been shown to reduce CCl4-induced liver injury and the development of metabolic dysfunction-associated steatotic liver disease (MASLD) in mice.
“Similarly, serum amyloid P has been shown to reduce CCl4-induced liver injury and the development of metabolic dysfunction-associated steatotic liver disease (MASLD) in mice [54, 55].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 109 · Cited by 17
- Authors
- Pilling, D., Cox, N., Thomson, M. A., Karhadkar, T. R., & Gomer, R. H.
- Affiliations
- Texas A&M University (US)
- Corresponding author
- Pilling, Darrell
- Gomer, Richard H.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 189
- Issue
- 12
- Pages
- 2400-2413
- ISSN
- 0002-9440 (ISSN-L)
- PMC
- PMC6902115
- OpenAlex
- W2974136943
- Cited by
- 17
- References
- 109
- Citations by year
- 2025: 5 · 2024: 5 · 2023: 2 · 2022: 2 · 2020: 3
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- American Journal Of Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (HL118507)
- Topics
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Keywords
- serum amyloid P component, pentraxins, DC-SIGN, high-fat diet, adipose tissue inflammation, hepatic steatosis, liver inflammation, adipogenesis, glucose tolerance, IL-23, interferon, MCP-1, IL-10, anti-inflammatory cytokines, adipocyte size
- MeSH terms
- DC-Specific ICAM-3 Grabbing Nonintegrin, Adipose Tissue, Serum Amyloid P-Component, Animals, Fatty Liver, Hepatitis, Insulin Resistance, Male, Mice, Inbred C57BL, Obesity, Receptors, Cell Surface, Cell Adhesion Molecules, Mice, Knockout, Lectins, C-Type, Mice, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review